{
    "title": "AstraZeneca boosts COVID portfolio with RQ Bio deal",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10823965/AstraZeneca-bolsters-COVID-therapeutics-RQ-Bio-deal.html",
    "date": "2022-05-17",
    "keywords": [
        "deal",
        "covid",
        "rq",
        "grover",
        "portfolio",
        "tuesday",
        "bio",
        "astrazeneca",
        "antibody",
        "evusheld",
        "astrazenecas",
        "vaccine",
        "london",
        "licensing",
        "biotech",
        "addition",
        "sum",
        "drugmaker",
        "royalty",
        "part",
        "licence",
        "startup",
        "size",
        "cocktail",
        "none",
        "ceo",
        "hugo",
        "fry",
        "interview",
        "lab",
        "omicron",
        "access",
        "crop",
        "decline",
        "bestseller",
        "year",
        "pfizer",
        "moderna",
        "production",
        "shelf",
        "life",
        "benefit",
        "latch",
        "bodys",
        "cancer",
        "time",
        "use",
        "crisis",
        "understanding",
        "ability",
        "point",
        "lot",
        "opportunity",
        "recurrent",
        "company",
        "funding",
        "risk",
        "disease",
        "death",
        "range",
        "twitter",
        "jason",
        "barbara",
        "lewis"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}